A practical reference on peptide analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-28 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
=== Stability and half-lives === Of isotopes whose half-lives are known, the lighter isotopes usually have shorter half-lives. The three lightest known isotopes have half-lives of <50 μs; the lightest reported isotope 252Rf has a half-life of <1 μs. 256Rf, 258Rf, 260Rf are more stable at ~10 ms; 255Rf, 257Rf, 259Rf, and 262Rf live between 1 and 5 seconds; 261Rf, 265Rf, and 263Rf are more stable, at ~1.1, 1.5, and 10 minutes respectively. The most stable known isotope, 267Rf, is one of the heaviest, and has a half-life of about 48 minutes. Rutherfordium isotopes with an odd neutron number tend to have longer half-lives than their even–even neighbors because the odd neutron hinders spontaneous fission. The lightest isotopes were synthesized by direct fusion between two lighter nuclei and as decay products. The heaviest isotope produced by direct fusion is 262Rf; heavier isotopes have only been observed as decay products of elements with larger atomic numbers. The heavy isotopes 266Rf and 268Rf have also been reported as electron capture daughters of the dubnium (266Db and 268Db), but have short half-lives to spontaneous fission. It seems likely that the same is true for 270Rf, a possible daughter of 270Db. These three isotopes remain unconfirmed. In 1999, American scientists at University of California, Berkeley, announced that they had succeeded in synthesizing three atoms of 293Og. These parent nuclei were reported to have successively emitted seven alpha particles to form 265Rf, but their claim was retracted in 2001.
A potentially controversial method of producing biopharmaceuticals involves transgenic organisms, particularly plants and animals that have been genetically modified to produce drugs. This production is a significant risk for its investor due to production failure or scrutiny from regulatory bodies based on perceived risks and ethical issues. Biopharmaceutical crops also represent a risk of cross-contamination with non-engineered crops, or crops engineered for non-medical purposes. One potential approach to this technology is the creation of a transgenic mammal that can produce the biopharmaceutical in its milk, blood, or urine. Once an animal is produced, typically using the pronuclear microinjection method, it becomes efficacious to use cloning technology to create additional offspring that carry the favorable modified genome. The first such drug manufactured from the milk of a genetically modified goat was ATryn, but marketing permission was blocked by the European Medicines Agency in February 2006. This decision was reversed in June 2006 and approval was given August 2006.
==== Miscellaneous laurasiatherian research ==== A study on the preservation of different kinds of steroids in bones of Ashoroa laticosta, Behemotops katsuiei and an unidentified whale from the Oligocene Morawan Formation (Japan) is published by Umamaheswaran et al. (2026). Matsui, Mitoh & Tsubamoto (2026) identify a purported humerus of a member of the genus Behemotops from the Miocene Chikubetsu Formation (Japan) as actually belonging to a juvenile member of the genus Desmostylus, and interpret the specimen as indicating that members of the genus Desmostylus expanded their range across Hokkaido during the Middle Miocene Climatic Optimum. Kramarz & Bond (2026) revise the composition of astrapothere assemblages from the Las Flores Formation (Argentina). Evidence of gradual increase of body mass of macraucheniids throughout their evolutionary history, likely linked to climate changes, is presented by Lobo, Gelfo & de Azevedo (2026). Wilson et al. (2026) determine that early hypsodont notoungulates from the Oligocene Tinguiririca Fauna (Chile) lived in an open, woody habitat, interpret the tooth wear of the studied notoungulates as consistent with a browsing diet, and interpret the evolution of their hypsodonty as unrelated to the expansion of grasslands. Redescription of the anatomy of Puelia plicata is published by Vera, Folino & Scarano (2026). A study on the phylogenetic relationships of toxodontid notoungulates is published by Armella & Deforel (2026). Armella et al.
Sources: en.wikipedia.org
Lt. Col. J. H. Fuller (18 April 1909 – 1 April 1911) Maj. Gordon Vallancy Drury (1 April 1911 – 28 January 1913) Maj. Gen. Sir Alfred Hamilton Mackenzie Edwards (28 January 1913 – 23 January 1923) Col. Algernon Essex Capell (1 February 1923 – 11 February 1926) Alfred James Tomlinson (12 February 1926 – 12 May 1926; acting) Col. George Stops (13 May 1926 – 14 February 1933) Brig. John Sidney Morris (15 February 1933 – 24 April 1945) Brig. John Ellis "Jack" Ross (24 April 1945 – 6 December 1950) Col. James Appleby (7 December 1950 – 2 June 1954) Col. Arthur Selwyn Hickman (3 June 1954 – 5 November 1955) Col. Harold Jackson (6 November 1955 – 12 March 1958) Basil Gordon Spurling (13 March 1958 – 25 April 1963) Frank Eric Barfoot (26 April 1963 – 2 January 1968) James Spink (3 January 1968 – 26 June 1970) Sydney Frederick Samuel Bristow (27 June 1970 – 6 February 1974) Peter Dennis Wray Richard Sherren (7 February 1974 – 6 February 1978) Peter Kevin Allum (7 February 1978 – 6 February 1982)
In April 1918, after the German-Russian Treaty of Brest-Litovsk, Austrian Foreign Minister Count Ottokar Czernin made a speech attacking incoming French Prime Minister Georges Clemenceau as being the main obstacle to a peace favouring the Central Powers. Clemenceau was incensed and, after seeing Emperor Charles's letter of 24 March 1917, had it published. For a while, the life of Sixtus appeared to be in danger, and there were even fears that Germany might occupy Austria. Czernin persuaded Charles to send a 'Word of Honour' to Austria's allies saying that Sixtus had not been authorised to show the letter to the French Government, that Belgium had not been mentioned, and that Clemenceau had lied about the mention of Alsace. Czernin had actually been in contact with the German Embassy throughout the whole crisis and attempted to persuade the Emperor to step down because of the Affair. After failing to do so, Czernin resigned as Foreign Minister.
Animal models have shown that at the enterocyte cell wall, β-carotene is taken up by the membrane transporter protein scavenger receptor class B, type 1 (SCARB1). Absorbed β-carotene is converted to retinal and then retinol. The first step of the conversion process consists of one molecule of β-carotene cleaved by the enzyme β-carotene-15, 15'-monooxygenase, which in humans and other mammalian species is encoded by the BCM01 gene, into two molecules of retinal. When plasma retinol is in the normal range, gene expression for SCARB1 and BC01 are suppressed, creating a feedback loop that suppresses β-carotene absorption and conversion. Absorption suppression is not complete, as receptor 36 is not downregulated.
=== Economic warfare === In response to the naval blockade of the French coasts enacted by the British government on 16 May 1806, Napoleon issued the Berlin Decree on 21 November 1806, which brought into effect the Continental System. This policy aimed to eliminate the threat from Britain by closing French-controlled territory to its trade. Britain maintained a standing army of 220,000 at the height of the Napoleonic Wars, of whom less than 50% were available for campaigning. The rest were necessary for garrisoning Ireland and the colonies and providing security for Britain. France's strength peaked at around 2,500,000 full-time and part-time soldiers including several hundred thousand National Guardsmen whom Napoleon could draft into the military if necessary. Both nations enlisted large numbers of sedentary militia who were unsuited for campaigning and were mostly employed to release regular forces for active duty. The Royal Navy disrupted France's extra-continental trade by seizing and threatening French shipping and colonial possessions, but could do nothing about France's trade with the major continental economies, and posed little threat to French territory in Europe. France's population and agricultural capacity greatly outstripped Britain's. Britain had the greatest industrial capacity in Europe, and its mastery of the seas allowed it to build up considerable economic strength through trade. This ensured that France could never consolidate its control over Europe in peace.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.